Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1961 1
1978 8
1979 6
1980 3
1982 4
1983 6
1984 7
1985 8
1986 9
1987 15
1988 7
1989 4
1990 9
1991 16
1992 24
1993 20
1994 23
1995 19
1996 14
1997 24
1998 23
1999 26
2000 35
2001 44
2002 54
2003 67
2004 64
2005 73
2006 93
2007 87
2008 100
2009 133
2010 171
2011 170
2012 168
2013 186
2014 216
2015 237
2016 233
2017 219
2018 192
2019 219
2020 229
2021 251
2022 228
2023 239
2024 238
2025 240
2026 157

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,101 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial.
Lafayette R, Tumlin J, Fenoglio R, Kaufeld J, Pérez Valdivia MÁ, Wu MS, Susan Huang SH, Alamartine E, Kim SG, Yee M, Kateifides A, Rice K, Garlo K, Barratt J; SANCTUARY Study Investigators. Lafayette R, et al. Among authors: kim sg. J Am Soc Nephrol. 2025 Apr 1;36(4):645-656. doi: 10.1681/ASN.0000000534. Epub 2024 Oct 25. J Am Soc Nephrol. 2025. PMID: 39455063 Free PMC article.
Povetacicept for IgA Nephropathy and Primary Membranous Nephropathy.
Madan A, Yalavarthy R, Kim DK, Moon JY, Park I, Mandayam S, Cortazar F, Kim SG, Enstrom A, Thomas H, Li J, Peng SL, Chen YC, Sanders J, Egbuna O, Tumlin J; AIS-D03 RUBY-3 Study Group. Madan A, et al. Among authors: kim sg. Kidney Int Rep. 2025 Nov 3;11(1):106-116. doi: 10.1016/j.ekir.2025.10.029. eCollection 2026 Jan. Kidney Int Rep. 2025. PMID: 41541780 Free PMC article.
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.
Horn DB, Ryan DH, Kis SG, Alves B, Mu Y, Kim SG, Aberle J, Bain SC, Allen S, Sarker E, Wu Q, Stefanski A, Jouravskaya I; ATTAIN-2 Trial Investigators. Horn DB, et al. Among authors: kim sg. Lancet. 2026 Dec 20;406(10522):2927-2944. doi: 10.1016/S0140-6736(25)02165-8. Epub 2025 Nov 20. Lancet. 2026. PMID: 41275875 Clinical Trial.
Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial.
Vaduganathan M, Green JB, Heerspink HJL, Kim SG, Mann JFE, McGill JB, Mottl A, Nangaku M, Rosenstock J, Rossing P, Li L, Li N, Rohwedder K, Scott C, Agarwal R. Vaduganathan M, et al. Among authors: kim sg. Nephrol Dial Transplant. 2025 Dec 23;41(1):161-170. doi: 10.1093/ndt/gfaf160. Nephrol Dial Transplant. 2025. PMID: 40886054 Free PMC article. Clinical Trial.
4,101 results